| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $38.9M | +4.8% | +90.4% |
| SG&A Expense | $9.1M | -28.4% | -6.9% |
| Operating Income | -$48.0M | +3.7% | -64.3% |
| Net Income | -$47.7M | +3.1% | -75.6% |
| EPS (Basic) | -$2.03 | +13.2% | -56.2% |
| EPS (Diluted) | -$2.03 | +13.2% | -56.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $26.1M | -38.6% | -71.9% |
| Short-term Investments | $0 | -100.0% | -100.0% |
| Current Assets | $28.9M | -40.3% | -82.1% |
| Total Assets | $72.4M | -24.7% | -69.1% |
| Current Liabilities | $44.7M | +42.7% | +61.8% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$109.7M | — | — |
| Capital Expenditures | $482K | — | — |
| Investing Cash Flow | $65.0M | — | — |
| Financing Cash Flow | $10.0M | — | — |
| Free Cash Flow | -$110.1M | — | — |
| $128.1M |
| +10.0% |
| +41.9% |
| Stockholders' Equity | -$55.7M | -175.3% | -138.6% |